Nicotinic acid– and monomethyl fumarate–induced flushing involves GPR109A expressed by keratinocytes and COX-2–dependent prostanoid formation in mice

Whatʼs the deal with niacin development: is laropiprant add-on therapy a winning strategy to beat a straight flush?

(2009) Harold E Bays et al.   CURRENT OPINION IN LIPIDOLOGY

Nicotinic acid and the prevention of coronary artery disease

(2009) Janet E Digby et al.   CURRENT OPINION IN LIPIDOLOGY

Extended-Release Niacin (Nicotinic Acid)/Laropiprant

(2009) Caroline M. Perry   DRUGS

The mechanism and mitigation of niacin-induced flushing

(2009) V. S. Kamanna et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

β-Arrestin1 mediates nicotinic acid–induced flushing, but not its antilipolytic effect, in mice

(2009) Robert W. Walters et al.   JOURNAL OF CLINICAL INVESTIGATION

Psoriasis

(2009) Frank O. Nestle et al.   NEW ENGLAND JOURNAL OF MEDICINE

The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist

(2008) Hua Tang et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Fumaric acid esters

(2008) Martin Rostami Yazdi et al.   CLINICS IN DERMATOLOGY

3-(1H-Tetrazol-5-yl)-1,4,5,6-tetrahydro-cyclopentapyrazole (MK-0354): A Partial Agonist of the Nicotinic Acid Receptor, G-Protein Coupled Receptor 109a, with Antilipolytic but No Vasodilatory Activity in Mice

(2008) Graeme Semple et al.   JOURNAL OF MEDICINAL CHEMISTRY

Isolation and short-term culture of primary keratinocytes, hair follicle populations and dermal cells from newborn mice and keratinocytes from adult mice for in vitro analysis and for grafting to immunodeficient mice

(2008) Ulrike Lichti et al.   Nature Protocols

Effects of Laropiprant on Nicotinic Acid-Induced Flushing in Patients With Dyslipidemia††A list of study investigators appears in the Appendix.

(2007) John F. Paolini et al.   AMERICAN JOURNAL OF CARDIOLOGY

Nicotinic Acid: Pharmacological Effects and Mechanisms of Action

(2007) Andreas Gille et al.   Annual Review of Pharmacology and Toxicology